Protalix Biotherapeutics Inc (PLX) — Cash Flow Reinvestment Rate

Latest as of December 2025: 0.61x

Protalix Biotherapeutics Inc (PLX) has a Cash Flow Reinvestment Rate of 0.61x as of December 2025, reinvesting $1.24 Million (capex $1.24 Million ) from operating cash flow of $2.03 Million. See cash generation quality of Protalix Biotherapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.61x
(Capex + Investments) / Operating CF

Total Reinvested

$1.24 Million
Capex + Investments

Operating Cash Flow

$2.03 Million
USD

Capital Expenditures

$1.24 Million
USD

Protalix Biotherapeutics Inc Cash Flow Reinvestment Rate (2009–2024)

Historical reinvestment intensity for Protalix Biotherapeutics Inc across 3 annual periods. For the full cash flow conversion analysis, see how efficiently does Protalix Biotherapeutics Inc generate cash.

Annual Cash Flow Reinvestment Rate for Protalix Biotherapeutics Inc (2009–2024)

Year-by-year capital reinvestment analysis for Protalix Biotherapeutics Inc. See financial flexibility index of Protalix Biotherapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 0.63x $5.50 Million $8.67 Million $1.28 Million ▼ -80.5%
2012 3.26x $2.07 Million $635.00K $2.07 Million ▲ +2236.8%
2009 0.14x $6.20 Million $44.45 Million $6.20 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow